VX-445 is a small molecule drug that is being developed as a potential treatment for cystic fibrosis (CF). It is designed to target the underlying cause of CF, which is a defective protein called CFTR. VX-445 works by helping the CFTR protein function more effectively, which can improve lung function and reduce the symptoms of CF. Clinical trials have shown promising results for VX-445, and it is currently being evaluated for approval by regulatory agencies as a possible new treatment option for CF patients.